Mayer-Hamblett N - Search Results

1

Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.

Mayer-Hamblett N, Saiman L, Lands LC, Anstead M, Rosenfeld M, Kloster M, Fisher L, Ratjen F. Mayer-Hamblett N, et al. Contemp Clin Trials. 2013 Sep;36(1):99-105. doi: 10.1016/j.cct.2013.06.004. Epub 2013 Jun 14. Contemp Clin Trials. 2013. PMID: 23770109 Clinical Trial.

2

Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.

Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Mayer-Hamblett N, et al. Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 1):1550-5. doi: 10.1164/rccm.200202-087OC. Epub 2002 Aug 15. Am J Respir Crit Care Med. 2002. PMID: 12406843

3

The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.

Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW. Goss CH, et al. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1505-28. doi: 10.1016/s0169-409x(02)00163-1. Adv Drug Deliv Rev. 2002. PMID: 12458158 Review.

4

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Smith AL, et al. Chest. 2003 May;123(5):1495-502. doi: 10.1378/chest.123.5.1495. Chest. 2003. PMID: 12740266

5

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group. Saiman L, et al. JAMA. 2003 Oct 1;290(13):1749-56. doi: 10.1001/jama.290.13.1749. JAMA. 2003. PMID: 14519709 Clinical Trial.

6

Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.

Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Goss CH, et al. Thorax. 2004 Nov;59(11):955-9. doi: 10.1136/thx.2003.017707. Thorax. 2004. PMID: 15516471 Free PMC article.

7

Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.

Mayer-Hamblett N, Kronmal RA. Mayer-Hamblett N, et al. Contemp Clin Trials. 2005 Feb;26(1):2-16. doi: 10.1016/j.cct.2004.08.008. Epub 2005 Jan 27. Contemp Clin Trials. 2005. PMID: 15837448

8

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.

Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC; Macrolide Study Group. Saiman L, et al. Am J Respir Crit Care Med. 2005 Oct 15;172(8):1008-12. doi: 10.1164/rccm.200502-218OC. Epub 2005 Jul 22. Am J Respir Crit Care Med. 2005. PMID: 16040785 Clinical Trial.

9

Laboratory parameter profiles among patients with cystic fibrosis.

Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW. Goss CH, et al. J Cyst Fibros. 2007 Apr;6(2):117-23. doi: 10.1016/j.jcf.2006.05.012. Epub 2006 Jul 7. J Cyst Fibros. 2007. PMID: 16829217 Free article.

10

Association between pulmonary function and sputum biomarkers in cystic fibrosis.

Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Mayer-Hamblett N, et al. Am J Respir Crit Care Med. 2007 Apr 15;175(8):822-8. doi: 10.1164/rccm.200609-1354OC. Epub 2007 Jan 18. Am J Respir Crit Care Med. 2007. PMID: 17234902 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters